IPO Update: TransCode Therapeutics Pursues $25 Million IPO (Pending:RNAZ)

TransCode Therapeutics has filed preliminary conditions for a $25 million initial public offering. The company is developing therapy options for a variety of metastatic malignancies./nRead More